AT
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AT, covering 2020-08-05 to 2024-01-22. Get the full timeline:
Most recent: Clinical Trial Update: A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer [Phase 2]